Ara
Toplam kayıt 6, listelenen: 1-6
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy (vol 23, 136, 2023)
(BMC, 2023)
Following publication of the original article [1], the authors reported an error in the author name of Enes Erul.
Efficacy of proprioceptive neuromuscular facilitation in improving shoulder biomechanical parameters, functionality, and pain after axillary lymph node dissection for breast cancer: A randomized controlled study
(Elsevier Science Ltd, 2023)
Purpose: Axillary lymph node dissection and radiotherapy have been associated with pain, physical symptoms, and decreased functional abilities in the upper extremity. This study aimed to evaluate the potential effects of ...
Intra-operative partial breast irradiation versus external whole breast irradiation for early breast cancer
(NLM (Medline), 2023)
Aims: Intra-operative radiotherapy (IORT) is a new alternative way to give radiation therapy. During surgery to remove breast cancer, radiation is given as a single dose directly to the area where the tumor used to be. The ...
Quantitative measurement of HER2/neu oncogene amplification and p53 tumor suppressor gene deletion by RT-PCR in breast cancer
(Istanbul University Press, 2023)
Objective: The aim of the study was to quantitatively evaluate HER2/neu oncogene amplification and p53 tumor suppressor gene deletion in breast cancer with real-time polymerase chain reaction (RT-PCR). Materials and Methods: ...
Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer
(Taylor and Francis Ltd., 2023)
To evaluate the tumour-infiltrating lymphocyte (TIL) rates in breast tissue before and after neoadjuvant chemotherapy (NAC) and their impact on survival, eighty-four patients with locally advanced breast cancer (LABC) were ...
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: A multicenter real-life HER2PATH study
(Taylor & Francis Ltd, 2023)
AimTo investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab (H) plus neoadjuvant chemotherapy (NCT) in HER2+ breast cancer (BC) ...